In China, brigatnib was approved for the first-line treatment option of patients diagnosed with ALK-positive locally advanced or metastatic NSCLC by the marketing approval from the China National Food and Drug Administration on 24 March 2022. Here, ALK is linked to non-small cell lung carcinoma.